Special Therapies

Merck Serono's vision is to improve and maintain the quality of life for people with metabolic disorders. Our first recombinant product, human growth hormone (r-hGH)) was launched in Australia in 1992.
Merck Serono has a paediatric focus. We are committed to providing support to children undergoing growth hormone treatment through specialised healthcare professionals. As therapy may continue over many years, we provide a range of educational materials and support to ensure children gain the most from their therapy at this important time in their development.
  • Growth Hormone Deficiency (GHD) occurs due to problems in the production and secretion of this hormone by the pituitary gland
  • GHD in children can cause growth retardation where normal growth is slowed or even stopped, but it can be successfully treated
    Growing up is a natural process. However, not every child experiences what is considered to be normal growth activity and this can have a detrimental effect on the child and their family.
The growth of an infant into an adult is a complex process involving a number of genes and hormones, as well as nutrition, diet, exercise, and rest. Growth hormone is central to growth and development, and is the principal hormone governing eventual height in an individual.
Growth retardation is a medical condition in which the normal growth of children is slowed down or even stopped. Some children grow more slowly due to a deficiency of growth hormone or, less commonly, due to other problems such as genetic abnormalities - for example Turner Syndrome.
Merck Serono has focused on providing a range of patient care programs that primarily provide support to improve patient care.
Merck Serono is a world leader in the development of novel biotechnology therapies for specific diseases. Our new treatment for psoriasis is the first of several in development specifically for the dermatology market. Dermatology, along with new therapeutic areas such as gastroenterology, rheumatology, oncology and others, will form a major part of Merck Serono's future.

SERVICES